LIVIVO - Search results -

Search results

Result 1 - 10 of total 51

Search options

Article ; Online: Hyperbaric Oxygen Therapy for Management of Late Radiation Toxicity-A Honey of a Trial?

Hahn, Ezra / Popovtzer, Aron / Corn, Benjamin W

JAMA oncology

2024 Volume 10, Issue 4, Page(s) 437–438

MeSH term(s)	Humans ; Hyperbaric Oxygenation ; Honey ; Radiation Injuries
Language	English
Publishing date	2024-02-06
Publishing country	United States
Document type	Journal Article
ISSN	2374-2445
ISSN (online)	2374-2445
DOI	10.1001/jamaoncol.2023.6698
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Small Changes, Big Impact: Excitement and Caution in Dose and Volume Reduction for Nasopharyngeal Carcinoma Radiation Therapy After Induction Chemotherapy.

Hahn, Ezra / Ng, Wai Tong

International journal of radiation oncology, biology, physics

2023 Volume 117, Issue 4, Page(s) 925–927

MeSH term(s)	Humans ; Nasopharyngeal Carcinoma/pathology ; Induction Chemotherapy ; Nasopharyngeal Neoplasms/drug therapy ; Nasopharyngeal Neoplasms/radiotherapy ; Carcinoma/pathology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin ; Neoplasm Staging ; Chemoradiotherapy/adverse effects
Chemical Substances	Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2023-07-28
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	197614-x
ISSN	1879-355X ; 0360-3016
ISSN (online)	1879-355X
ISSN	0360-3016
DOI	10.1016/j.ijrobp.2023.06.276
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Leveraging the Potential of Induction Therapy in Human Papillomavirus-Mediated Oropharyngeal Carcinoma.

Hahn, Ezra / Huang, Shao Hui

International journal of radiation oncology, biology, physics

2023 Volume 118, Issue 1, Page(s) 179–181

MeSH term(s)	Humans ; Human Papillomavirus Viruses ; Induction Chemotherapy ; Oropharyngeal Neoplasms/radiotherapy ; Oropharyngeal Neoplasms/pathology ; Carcinoma, Squamous Cell/pathology ; Papillomavirus Infections/complications ; Papillomaviridae
Language	English
Publishing date	2023-11-11
Publishing country	United States
Document type	Editorial
ZDB-ID	197614-x
ISSN	1879-355X ; 0360-3016
ISSN (online)	1879-355X
ISSN	0360-3016
DOI	10.1016/j.ijrobp.2023.09.035
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Are we ready for deintensification in human papillomavirus-positive oropharyngeal carcinomas?

Huang, Shao Hui / Hahn, Ezra / Salunkhe, Rohan / Barcelona, Marc Vincent N / O'Sullivan, Brian

Current opinion in otolaryngology & head and neck surgery

2023 Volume 31, Issue 2, Page(s) 118–128

Abstract: Purpose of review: Excellent outcomes following contemporary treatment of human papillomavirus (HPV)-positive oropharyngeal carcinoma (HPV+ OPC) have prompted the exploration of deintensification approaches to minimize treatment-related toxicities. This ...

Abstract	Purpose of review: Excellent outcomes following contemporary treatment of human papillomavirus (HPV)-positive oropharyngeal carcinoma (HPV+ OPC) have prompted the exploration of deintensification approaches to minimize treatment-related toxicities. This review describes the landscape of deintensification to date (up to November 2022). Recent findings: Although several deintensification trials have been published, none are practice changing. Three phase III randomized-controlled trials studying cetuximab and radiation therapy vs. standard chemoradiotherapy all showed inferior outcomes. Although some phase II trials reported favourable outcomes, they are often single-arm trials without an adequate control arm, thereby limiting the ability to modify practice. Summary: Substantial effort has been expended to explore deintensification options for selected HPV+ OPC patients aiming to avoid unnecessary toxicity. Strategies have included replacing cisplatin with cetuximab, reduced chemotherapy or radiotherapy intensity, reduction of radiotherapy volumes and risk stratification after trans-oral surgery or following induction chemotherapy. Challenges remain in the current deintensification landscape, including identifying the most suitable candidates along with a choice of most appropriate deintensification strategies. Promising selection criteria included either static baseline features or kinetic characteristics of clinical-biological parameters. Practice-changing trials remain elusive, and the search continues to attempt optimization of the therapeutic ratio for these patients.
MeSH term(s)	Humans ; Human Papillomavirus Viruses ; Cetuximab ; Papillomavirus Infections ; Oropharyngeal Neoplasms/pathology ; Chemoradiotherapy ; Carcinoma
Chemical Substances	Cetuximab (PQX0D8J21J)
Language	English
Publishing date	2023-01-31
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	1232518-1
ISSN	1531-6998 ; 1068-9508
ISSN (online)	1531-6998
ISSN	1068-9508
DOI	10.1097/MOO.0000000000000871
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4814: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?

Hahn, Ezra / Rodin, Danielle / Sutradhar, Rinku / Nofech-Mozes, Sharon / Trebinjac, Sabina / Paszat, Lawrence Frank / Rakovitch, Eileen

Current oncology (Toronto, Ont.)

2023 Volume 30, Issue 6, Page(s) 5795–5806

Abstract: Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing ... ...

Abstract	Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing treatment approach in order to reduce the risk of local recurrence (LR), including invasive LR, which carries a subsequent risk of breast cancer mortality. However, reliable and accurate individual risk prediction remains elusive and RT continues to be standardly recommended for most women with DCIS. Three molecular biomarkers have been studied to better estimate LR risk after BCS-Oncotype DX DCIS score, DCISionRT Decision Score and its associated Residual Risk subtypes, and Oncotype 21-gene Recurrence Score. All these molecular biomarkers represent important efforts towards improving predicted risk of LR after BCS. To prove clinical utility, these biomarkers require careful predictive modeling with calibration and external validation, and evidence of benefit to patients; on this front, further research is needed. Most trials do not incorporate molecular biomarkers in evaluating de-escalation of therapy for DCIS; however, one-the Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk DCIS (ELISA) trial-incorporates the Oncotype DX DCIS score in defining a low-risk population and is an important next step in this line of research.
MeSH term(s)	Female ; Humans ; Carcinoma, Intraductal, Noninfiltrating/diagnosis ; Carcinoma, Intraductal, Noninfiltrating/genetics ; Carcinoma, Intraductal, Noninfiltrating/therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; Breast Neoplasms/diagnosis ; Risk ; Biomarkers, Tumor/genetics ; Overtreatment
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2023-06-13
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol30060433
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.

Botta, Gregory P / Chao, Joseph / Ma, Hong / Hahn, Michael / Sierra, Gloria / Jia, Jie / Hendrix, Amanda Y / Nolte Fong, Joy V / Ween, Audrey / Vu, Peter / Miller, Aaron / Choi, Michael / Heyman, Benjamin / Daniels, Gregory A / Kaufman, Dan / Jamieson, Catriona / Li, Zonghai / Cohen, Ezra

Journal for immunotherapy of cancer

2024 Volume 12, Issue 2

Abstract: Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients with otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell ... ...

Abstract	Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients with otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell treatment of solid tumors, including advanced gastric cancer (GC), has proven more challenging due to on-target off-tumor toxicities, poor tumor T-cell infiltration, inefficient CAR T-cell expansion, immunosuppressive tumor microenvironments, and demanding preconditioning regimens. We report the exceptional results of autologous Claudin18.2-targeted CAR T cells (CT041) in a patient with metastatic GC, who had progressed on four lines of combined systemic chemotherapy and immunotherapy. After two CT041 infusions, the patient had target lesion complete response and sustained an 8-month overall partial response with only minimal ascites. Moreover, tumor-informed circulating tumor DNA (ctDNA) reductions coincided with rapid CAR T-cell expansion and radiologic response. No severe toxicities occurred, and the patient's quality of life significantly improved. This experience supports targeting Claudin18.2-positive GC with CAR T-cell therapy and helps to validate ctDNA as a biomarker in CAR T-cell therapy.
MeSH term(s)	Humans ; Receptors, Antigen, T-Cell ; Stomach Neoplasms/therapy ; Quality of Life ; T-Lymphocytes ; Receptors, Chimeric Antigen ; Pathologic Complete Response ; Antigens, CD19 ; Leukemia ; Tumor Microenvironment
Chemical Substances	Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; Antigens, CD19
Language	English
Publishing date	2024-02-05
Publishing country	England
Document type	Journal Article
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2023-007927
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Levamisole-induced Vasculitis in a Cocaine User.

Hahn, Ezra / Bogoch, Isaac I

The Journal of rheumatology

2015 Volume 42, Issue 10, Page(s) 1924–1925

MeSH term(s)	Cocaine-Related Disorders/complications ; Debridement/methods ; Dexamethasone/administration & dosage ; Drug Contamination ; Female ; Humans ; Infusions, Intravenous ; Levamisole/adverse effects ; Middle Aged ; Necrosis/pathology ; Necrosis/therapy ; Rare Diseases ; Risk Assessment ; Treatment Outcome ; Vasculitis, Leukocytoclastic, Cutaneous/chemically induced ; Vasculitis, Leukocytoclastic, Cutaneous/pathology ; Vasculitis, Leukocytoclastic, Cutaneous/therapy
Chemical Substances	Levamisole (2880D3468G) ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2015-10
Publishing country	Canada
Document type	Case Reports ; Journal Article
ZDB-ID	194928-7
ISSN	1499-2752 ; 0315-162X
ISSN (online)	1499-2752
ISSN	0315-162X
DOI	10.3899/jrheum.150027
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 135: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Association Between Surgical Axillary Staging, Adjuvant Treatment Use and Survival in Older Women with Early Stage Breast Cancer: A Population-Based Study.

Castelo, Matthew / Sutradhar, Rinku / Faught, Neil / Mata, Danilo Giffoni M M / Hahn, Ezra / Nguyen, Lena / Paszat, Lawrence / Rodin, Danielle / Trebinjac, Sabina / Fong, Cindy / Rakovitch, Eileen

Annals of surgical oncology

2023 Volume 30, Issue 7, Page(s) 3901–3912

Abstract: Background: Choosing Wisely guidelines recommend against surgical axillary staging (AS) in women ≥70 years with ER+/HER2- early stage breast cancer (BC). This study examined the impact of AS omission on survival in older patients with BC.: Methods: ... ...

Abstract	Background: Choosing Wisely guidelines recommend against surgical axillary staging (AS) in women ≥70 years with ER+/HER2- early stage breast cancer (BC). This study examined the impact of AS omission on survival in older patients with BC. Methods: This was a population-based cohort study using health administrative data in Ontario, Canada. We identified women aged 65-95 years who underwent surgery for Stage I/II BC between 2010 and 2016. Patients were weighted by propensity scores for receipt of AS that included patient and disease characteristics using overlap weights. Association with overall survival (OS) was calculated using weighted Cox models, and breast cancer-specific survival (BCSS) was calculated using weighted Fine and Gray models, adjusting for biomarkers and adjuvant treatments. Adjuvant treatment receipt was modelled with weighted log-binomial models. Results: Among 17,370 older women, the 1771 (10.2%) who did not undergo AS were older, more comorbid, and less likely to undergo mastectomy. Women who did not undergo AS were less likely to receive adjuvant chemotherapy (RR 0.68, 95% CI 0.57-0.82), endocrine therapy (RR 0.85, 95% CI 0.81-0.89) or radiotherapy (RR 0.69, 95% CI 0.65-0.74). After weighting and adjustment, there was no significant difference in BCSS (sdHR 0.98, 95% CI 0.77-1.25), but women who did not undergo AS had worse OS (HR 1.14, 95% CI 1.04-1.25). The results among 6215 ER+/HER2- women ≥70 years undergoing SLNB vs no AS were similar. Conclusions: The omission of AS in older women with early stage BC was not associated with adverse BCSS, although OS was worse.
MeSH term(s)	Female ; Humans ; Aged ; Breast Neoplasms/surgery ; Breast Neoplasms/drug therapy ; Mastectomy ; Cohort Studies ; Breast/pathology ; Adjuvants, Immunologic/therapeutic use ; Ontario/epidemiology ; Neoplasm Staging
Chemical Substances	Adjuvants, Immunologic
Language	English
Publishing date	2023-03-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	1200469-8
ISSN	1534-4681 ; 1068-9265
ISSN (online)	1534-4681
ISSN	1068-9265
DOI	10.1245/s10434-023-13274-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4042: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Impact of non-adherence to endocrine therapy on recurrence risk in older women with stage I breast cancer after breast-conserving surgery.

Rodin, Danielle / Sutradhar, Rinku / Jerzak, Katarzyna J / Hahn, Ezra / Nguyen, Lena / Castelo, Matthew / Fatiregun, Omolara / Fong, Cindy / Mata, Danilo Giffoni M M / Trebinjac, Sabina / Paszat, Lawrence / Rakovitch, Eileen

Breast cancer research and treatment

2023 Volume 201, Issue 1, Page(s) 77–87

Abstract: Purpose: We examined the impact of non-adherence to adjuvant endocrine therapy (ET) on the risk and site of recurrence among older women with early stage, hormone receptor positive (HR+) breast cancer (EBC).: Methods: A population-based cohort of ... ...

Abstract	Purpose: We examined the impact of non-adherence to adjuvant endocrine therapy (ET) on the risk and site of recurrence among older women with early stage, hormone receptor positive (HR+) breast cancer (EBC). Methods: A population-based cohort of women age ≥ 65 years with T1N0 HR + EBC who were diagnosed between 2010 and 2016 and treated with breast-conserving surgery (BCS) + ET was identified. Treatment and outcomes were ascertained through linkage with administrative databases. ET non-adherence was examined as a time-dependent covariate in multivariable cause-specific Cox regression models to evaluate its effect on the risks of ipsilateral local recurrence (LR), contralateral breast cancer, and distant metastases. Results: The population cohort includes 2637 women; 73% (N = 1934) received radiation (RT) + ET and 27% (N = 703) received ET alone. At a median follow-up of 8.14 years, the first event was LR in 3.6% of women treated with ET alone and 1.4% for those treated with RT + ET (p < 0.001); the risk of distant metastases was < 1% in both groups. The proportion of time adherent to ET was 69.0% among those treated with RT + ET and 62.8% for those treated with ET alone. On multivariable analysis, increasing proportion of time non-adherent to ET was associated with increased risk of LR ((HR = 1.52 per 20% increase in time; 95%CI 1.25, 1.85; p < 0.001), contralateral BC (HR = 1.55; 95%CI 1.30, 1.84; p < 0.001), and distant metastases (HR = 1.44; 95%CI 1.08, 1.94; p = 0.01) but absolute risks were low. Conclusion: Non-adherence to adjuvant ET was associated with an increased risk of recurrence, but absolute recurrence rates were low.
MeSH term(s)	Female ; Humans ; Aged ; Breast Neoplasms/drug therapy ; Breast Neoplasms/surgery ; Mastectomy, Segmental ; Neoplasm Staging ; Risk ; Combined Modality Therapy ; Neoplasm Recurrence, Local/pathology
Language	English
Publishing date	2023-06-16
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	604563-7
ISSN	1573-7217 ; 0167-6806
ISSN (online)	1573-7217
ISSN	0167-6806
DOI	10.1007/s10549-023-06989-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Causes and impact of delays during the COVID-19 pandemic on head and neck cancer diagnosis.

Head & neck

2024

Abstract: Background: The causes for delays during the COVID19 pandemic and their impact on head and neck cancer (HNC) diagnosis and staging are not well described.: Methods: Two cohorts were defined a priori for review and analysis-a Pre-Pandemic cohort (June ...

Abstract	Background: The causes for delays during the COVID19 pandemic and their impact on head and neck cancer (HNC) diagnosis and staging are not well described. Methods: Two cohorts were defined a priori for review and analysis-a Pre-Pandemic cohort (June 1 to December 31, 2019) and a Pandemic cohort (June 1 to December 31, 2020). Delays were categorized as COVID-19 related or not, and as clinician, patient, or policy related. Results: A total of 638 HNC patients were identified including 327 in the Pre-Pandemic Cohort and 311 in the Pandemic Cohort. Patients in the Pandemic cohort had more N2-N3 category (41% vs. 33%, p = 0.03), T3-T4 category (63% vs. 50%, p = 0.002), and stage III-IV (71% vs. 58%, p < 0.001) disease. Several intervals in the diagnosis to treatment pathway were significantly longer in the pandemic cohort as compared to the Pre-Pandemic cohort. Among the pandemic cohort, 146 (47%) experienced a delay, with 112 related to the COVID-19 pandemic; 80 (71%) were clinician related, 15 (13%) were patient related, and 17 (15%) were policy related. Conclusions: Patients in the Pandemic cohort had higher stage disease at diagnosis and longer intervals along the diagnostic pathway, with COVID-19 related clinician factors being the most common cause of delay.
Language	English
Publishing date	2024-04-25
Publishing country	United States
Document type	Journal Article
ZDB-ID	645165-2
ISSN	1097-0347 ; 0148-6403 ; 1043-3074
ISSN (online)	1097-0347
ISSN	0148-6403 ; 1043-3074
DOI	10.1002/hed.27784
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1493: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito